Fig. 7: Ppar activation normalizes lipid droplet accumulation and decrease injury in differentiated Chkb^−/− myocytes in culture.

A To study the effect of Ppar agonist treatments on exogenous fatty acid utilization and storage, 4 days after differentiation, myocytes were treated with or without bezafibrate (500 μM) or GW501516 (2.5 μM) in the medium for 48 h. On day 6 of differentiation the medium with or without drugs was supplemented with Oleate-BSA (400 μM) overnight. On day 7 of differentiation cells were labeled with mitotracker® Red CMXRos (50 nM) for 30 min, washed with PBS, fixed and stained with BODIPY-493/503 to visualize LDs (Green). DAPI was used to stain nucleus (Blue). The images are representative of 3 independent experiments with similar results. Scale bar = 50 μm. B Summary of fold change and statistical tests performed on DG and TG. n = 3 independent samples per group. Pairwise Wilcoxon signed rank test with Bonferroni correction was used to determine the significance of a median pair-wise fold-increase in lipid amounts at an overall significance level of 5%. All statistical tests were two-sided. As the Bonferroni correction is fairly conservative, significant differences are reported at both pre-correction (*) and post-correction (***) significance levels. TG, triacylglycerol; DG, diacylglycerol. p = 0.0069 (DG) and p = 0.0007(TG). C RT-qPCR analysis of Icam1 gene expression in differentiated Chkb⁺⁺ myocyte and Chkb^−/− myocytes treated with ciprofibrate (50 μM), bezafibrate (500 μM) or GW501516 (2.5 μM) in the presence of 1 mM choline for 48 h on day 4 of differentiation. Values are means ± SD; n = 3 independent experiments. One-way ANOVA with Tukey’s multiple comparison test; p < 0.0001. #p < 0.01 (Chkb⁺⁺) vs all the other groups. **p < 0.01. Source data are provided as a Source Data file.